Consolidated Income Statement (IFRS)*

in €   Note   2012  2011  
Continuing Operations
Revenues 2.7, 4 51,916,986 82,077,245
Operating Expenses
Cost of Goods Sold 2.8, 3 0 0
Research and Development 37,673,345 55,878,828
Sales, General and Administrative 12,081,649 14,930,403
Total Operating Expenses 49,754,994 70,809,231
Other Income 6 415,477 533,502
Other Expenses 6 85,454 2,007,934
Earnings before Interest and Taxes (EBIT) 2,492,015 9,793,582
Finance Income 6 658,991 1,453,616
Finance Expenses 6 98,931 54,197
Income Tax Expenses 7 (685,812) (2,990,914)
Profit for the Year from Continuing Operations 2,366,263 8,202,087
(Loss) / Profit for the Year from Discontinued Operations 17 (424,118) 14,310
Consolidated Net Profit 1,942,145 8,216,397
Basic Net Profit per Share 8 0.08 0.36
thereof from Continuing Operations 8 0.10 0.36
thereof from Discontinued Operations 8 (0.02) 0.00
Diluted Net Profit per Share 8 0.08 0.36
thereof from Continuing Operations 8 0.10 0.35
thereof from Discontinued Operations 8 (0.02) 0.00
Shares Used in Computing Basic Net Profit per Share 8 23,004,894 22,887,723
Shares Used in Computing Diluted Net Profit per Share 8 23,260,360 23,126,158

See accompanying Notes

* Due to the Agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the segment AbD Serotec, for the years 2012 and 2011, revenue, income and expenses in connection with the transaction are shown in the line item ‘Profit for the Year from Discontinued Operations’. All other line items above ‘Net Profit’ consist of amounts from continuing operations. See also note 17 of these Notes.